TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotec...
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines...
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging...
Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase...
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases...
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases...
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells...
Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditions Continued work with computer-aided pre-clinical test...
Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related i...
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir's lead product candidate focused on reversing age-related decline and the extension of human life BALTIMORE...